Kalaris Therapeutics, Inc. reports a Return on Equity (ROE) of -64.32%.

What is KLRS's dividend yield?

Kalaris Therapeutics, Inc. offers a dividend yield of 0.00%.

What is KLRS's Quality Score?

Our AI rates KLRS's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy KLRS?

Our AI Timing Score for KLRS is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does KLRS belong to?

Kalaris Therapeutics, Inc. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Kalaris Therapeutics, Inc. (KLRS) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-03-31)

KLRS AI Analysis Summary

Our AI summary for KLRS: Kalaris Therapeutics, Inc. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -64.32%, a dividend yield of 0.00%. Its financial Quality Score stands at 15/100 — fundamentals below the market average. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

KLRS

Kalaris Therapeutics, Inc.

US:NASDAQ STOCK Healthcare >> Biotechnology News 88

USD 4.32

0.27 (6.67%) Day Change

Watchlist Portfolio Compare Chart

0.00

D/E

-64.3%

ROE

-40.2%

ROA

0.00%

Div Yield

KALARIS THERAPEUTICS, INC.
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 4.32 Price 0.27 (6.67%) Day Change	NEWS SCORE: 88

KLRS, the overall quality is not good ( Quality = 15) and the timing to buy is ...(Sign In to See)...

Loading chart...

15 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

41%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	88
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	4.32
PBV / Sector	1.41 / 44,022.72 GOOD
Earning Per Share	-1.98

PE / Sector	N/A / 19.17
PEG or PE/Growth / Sector	N/A / 1.24
Average 1M Daily Value	2.85 M GREAT
Average 1W Daily Value	0.40 M GREAT

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 98.24
NPM Average (%) / Sector	N/A / -1,697.63
NPM Change Average (%) / Sector	N/A / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-40.16 / 185,260.96
ROA Average (%) / Sector	-192.72 / 36,684.70
ROA Change Average (%) / Sector	-23.30 / 422,221.66
ROE (%) / Sector	-64.32 / 243,762.23
ROE Average (%) / Sector	-17.50 / 48,758.47
ROE Change Average (%) / Sector	-68.01 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.49

Registration Details

Analyze Date	2026-08-05 08:00:26
Symbol	KLRS
Name	KALARIS THERAPEUTICS, INC.
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	23.79 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	96.36 / 9,586.08

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 400 Connell Drive, Berkeley Heights, NJ, United States, 07922

Phone: 650 249 2727

Website: https://kalaristx.com

Sector: Healthcare >> Biotechnology

Description: Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.